• InMed Pharmaceuticals reported ADAR1 Capital Management as a 10% owner in an initial beneficial ownership filing dated May 19, 2026.
• The filing shows 331,449 common shares held indirectly through private investment funds managed by ADAR1.
• Daniel Schneeberger was listed as a reporting person alongside ADAR1.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001940272-26-000007), on May 21, 2026, and is solely responsible for the information contained therein.